ALN-AS1: Phase I started

Alnylam began a Phase I trial of subcutaneous ALN-AS1 in about 48 patients. The study comprises 2 single-blind, placebo-controlled, dose-escalation parts in up to 40 AIP patients who are asymptomatic ...